Cargando…
Foam Cell Specific LXRα Ligand
OBJECTIVE: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of atherosclerosis. METHODS AND RESULTS: We optimized a promising stilbenoi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581588/ https://www.ncbi.nlm.nih.gov/pubmed/23451202 http://dx.doi.org/10.1371/journal.pone.0057311 |
_version_ | 1782260447326502912 |
---|---|
author | Feldmann, Radmila Geikowski, Anne Weidner, Christopher Witzke, Annabell Kodelja, Vitam Schwarz, Thomas Gabriel, Mario Erker, Thomas Sauer, Sascha |
author_facet | Feldmann, Radmila Geikowski, Anne Weidner, Christopher Witzke, Annabell Kodelja, Vitam Schwarz, Thomas Gabriel, Mario Erker, Thomas Sauer, Sascha |
author_sort | Feldmann, Radmila |
collection | PubMed |
description | OBJECTIVE: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of atherosclerosis. METHODS AND RESULTS: We optimized a promising stilbenoid structure (STX4) in order to reach nanomolar effective concentrations in LXRα reporter-gene assays. STX4 displayed the unique property to activate LXRα effectively but not its subtype LXRβ. The potential of STX4 to increase transcriptional activity as an LXRα ligand was tested with gene expression analyses in THP1-derived human macrophages and oxLDL-loaded human foam cells. Only in foam cells but not in macrophage cells STX4 treatment showed athero-protective effects with similar potency as the synthetic LXR ligand T0901317 (T09). Surprisingly, combinatorial treatment with STX4 and T09 resulted in an additive effect on reporter-gene activation and target gene expression. In physiological tests the cellular content of total and esterified cholesterol was significantly reduced by STX4 without the undesirable increase in triglyceride levels as observed for T09. CONCLUSIONS: STX4 is a new LXRα-ligand to study transcriptional regulation of anti-atherogenic processes in cell or ex vivo models, and provides a promising lead structure for pharmaceutical development. |
format | Online Article Text |
id | pubmed-3581588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35815882013-02-28 Foam Cell Specific LXRα Ligand Feldmann, Radmila Geikowski, Anne Weidner, Christopher Witzke, Annabell Kodelja, Vitam Schwarz, Thomas Gabriel, Mario Erker, Thomas Sauer, Sascha PLoS One Research Article OBJECTIVE: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of atherosclerosis. METHODS AND RESULTS: We optimized a promising stilbenoid structure (STX4) in order to reach nanomolar effective concentrations in LXRα reporter-gene assays. STX4 displayed the unique property to activate LXRα effectively but not its subtype LXRβ. The potential of STX4 to increase transcriptional activity as an LXRα ligand was tested with gene expression analyses in THP1-derived human macrophages and oxLDL-loaded human foam cells. Only in foam cells but not in macrophage cells STX4 treatment showed athero-protective effects with similar potency as the synthetic LXR ligand T0901317 (T09). Surprisingly, combinatorial treatment with STX4 and T09 resulted in an additive effect on reporter-gene activation and target gene expression. In physiological tests the cellular content of total and esterified cholesterol was significantly reduced by STX4 without the undesirable increase in triglyceride levels as observed for T09. CONCLUSIONS: STX4 is a new LXRα-ligand to study transcriptional regulation of anti-atherogenic processes in cell or ex vivo models, and provides a promising lead structure for pharmaceutical development. Public Library of Science 2013-02-25 /pmc/articles/PMC3581588/ /pubmed/23451202 http://dx.doi.org/10.1371/journal.pone.0057311 Text en © 2013 Feldmann et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Feldmann, Radmila Geikowski, Anne Weidner, Christopher Witzke, Annabell Kodelja, Vitam Schwarz, Thomas Gabriel, Mario Erker, Thomas Sauer, Sascha Foam Cell Specific LXRα Ligand |
title | Foam Cell Specific LXRα Ligand |
title_full | Foam Cell Specific LXRα Ligand |
title_fullStr | Foam Cell Specific LXRα Ligand |
title_full_unstemmed | Foam Cell Specific LXRα Ligand |
title_short | Foam Cell Specific LXRα Ligand |
title_sort | foam cell specific lxrα ligand |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581588/ https://www.ncbi.nlm.nih.gov/pubmed/23451202 http://dx.doi.org/10.1371/journal.pone.0057311 |
work_keys_str_mv | AT feldmannradmila foamcellspecificlxraligand AT geikowskianne foamcellspecificlxraligand AT weidnerchristopher foamcellspecificlxraligand AT witzkeannabell foamcellspecificlxraligand AT kodeljavitam foamcellspecificlxraligand AT schwarzthomas foamcellspecificlxraligand AT gabrielmario foamcellspecificlxraligand AT erkerthomas foamcellspecificlxraligand AT sauersascha foamcellspecificlxraligand |